Flurbiprofen - CAS 5104-49-4
Catalog number:
5104-49-4
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C15H13FO2
Molecular Weight:
244.26
COA:
Inquire
Targets:
PGE Synthase
Description:
Flurbiprofen is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs) used to treat the inflammation and pain of arthritis.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system.
Chen H1, Pan H2, Li P1, Wang H3, Wang X1, Pan W1, Yuan Y4. Colloids Surf B Biointerfaces. 2016 Mar 22;143:455-462. doi: 10.1016/j.colsurfb.2016.03.061. [Epub ahead of print]
In this study, novel chitosan-coated deformable liposomes (DL-CS) were proposed as an ocular drug delivery system to prolong pre-corneal retention, and improve transcorneal penetration and absorption. Flurbiprofen-loaded deformable liposomes (FP-DL) were prepared by a modified ethanol injection method and then coated with chitosan. Both DL and DL-CS exhibited a homogeneous particle size distribution, high encapsulation efficiency and good stability. After coating with 0.1% CS, the zeta potential was shifted from negative to positive. The apparent permeability coefficient of FP-DL-0.1% CS evaluated using isolated rabbit corneas was 1.29-, 1.95- and 4.59- fold greater than that of uncoated FP-DL, conventional liposomes and FP solution (P<0.01), respectively. The in vivo pre-corneal retention time and elimination dynamics were assessed using gamma scintigraphy technology. The area under the remaining activity-time of FP-DL-0.1% CS was prolonged 2.
2.Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial.
de Looze F1, Russo M2, Bloch M3, Montgomery B4, Shephard A5, Smith G5, Aspley S5. Eur J Gen Pract. 2016 Mar 30:1-8. [Epub ahead of print]
Background Viral infections cause most cases of pharyngitis (sore throat); consequently, antibiotics are generally not warranted. However, a treatment targeting pain and inflammation, e.g. a topical non-steroidal anti-inflammatory spray, may be helpful for patients. Objective To evaluate the efficacy and safety of flurbiprofen 8.75 mg spray. Methods This randomised, double-blind, parallel group study was conducted at six community-based clinical research centres in Australia and two in New Zealand. Adults with sore throat due to upper respiratory tract infection (onset ≤ four days) took one dose of flurbiprofen (n = 249) or placebo spray (n = 256); after six hours, they could re-dose every three-six hours as required, for three days (max. five doses/day). The primary endpoint was the area under the change from baseline curve in throat soreness from zero-two hours (AUC0-2h). The change from baseline in other sore throat symptoms also assessed efficacy.
3.Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M1, Samer C1,2, Déglon J3,4, Thomas A3, Walder B5, Desmeules J1,2, Daali Y1,2. Basic Clin Pharmacol Toxicol. 2016 Mar 24. doi: 10.1111/bcpt.12586. [Epub ahead of print]
Cytochrome P450 (CYP) activity can be assessed using a 'cocktail' phenotyping approach. Recently, we have developed a cocktail (Geneva cocktail) which combines the use of low-dose probes with a low-invasiveness dried blood spots (DBS) sampling technique and a single analytical method for the phenotyping of six major CYP isoforms. We have previously demonstrated that modulation of CYP activity after pre-treatment with CYP inhibitors/inducer could be reliably predicted using Geneva cocktail. In order to further validate this cocktail, in this study we have verified whether probe drugs contained in the latter cause mutual drug-drug interactions. In a randomized, 4-way, Latin-square cross-over study, 30 healthy volunteers received low-dose caffeine, flurbiprofen, omeprazole, dextromethorphan and midazolam (a previously validated combination with no mutual drug-drug interactions); fexofenadine alone; bupropion alone or all 7 drugs simultaneously (Geneva cocktail).
4.INTERACTION OF CAMPTOTHECIN WITH HUMAN SERUM ALBUMIN DETERMINED BY FLUORESCENCE ANISOTROPY SPECTROSCOPY.
Wybranowski T, Ziomkowska B, Cyrankiewicz M, Kruszewski S. Acta Pol Pharm. 2016 Jan-Feb;73(1):29-34.
The study can be useful for understanding the interaction of camptothecin with human serum albu- min. There are two forms of camptothecin (the carboxylate form (CPT-C) and the lactone form (CPT-L)) but only the lactone one is pharmacologically active. It was reported earlier that in the presence of HSA, the active lactone form of camptothecin changes to inactive carboxylate form and it reduces the antitumor activities of camptothecin. However, those studies were performed at physiological pH (7.4) and with non-oxidized and non-glycosylated albumin. The aim of this study was to investigate the effect of oxidative stress, glycosylation, pH changes and competitor drugs on inactivation of lactone form of camptothecin in albumin solution using measurements of fluorescence anisotropy spectroscopy. It was tried to prove that in vivo camptothecin may be present in higher amount in lactone form than previously thought. Due to a reduction of pH value, a decreased rate of hydrolysis from CPT-L to CPT-C was observed.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PGE Synthase Products


CAS 64092-48-4 Zomepirac Sodium

Zomepirac Sodium
(CAS: 64092-48-4)

Zomepirac sodium salt is a prostaglandin synthetase inhibitor, was indicated for the management of mild to severe pain.

CAS 102271-49-8 PGS-IN-1

PGS-IN-1
(CAS: 102271-49-8)

PGS-IN-1 is a potent inhibitor of prostaglandin synthetase (PGS) (IC50= 0.28 μM) and also an inhibitor of 5-lipoxygenase (IC50= 1.05 μM).

CAS 89-57-6 Mesalamine

Mesalamine
(CAS: 89-57-6)

Mesalamine is an anti-inflammatory compound.

CAS 40828-46-4 Suprofen

Suprofen
(CAS: 40828-46-4)

A dual COX-1/COX-2 inhibitor

SAR191801
(CAS: 1234708-04-3)

SAR191801 is a hPGDS inhibitor and the IC50 value of which is 12 nM that was determined through fluorescence polarization.

CAS 52549-17-4 Pranoprofen

Pranoprofen
(CAS: 52549-17-4)

Pranoprofen (INN) is a non-steroidal anti-inflammatory drug used in ophthalmology.Pranoprofen is a PGE2 inhibitor with IC50 of 7.5 μM.

CAS 5104-49-4 Flurbiprofen

Flurbiprofen
(CAS: 5104-49-4)

Flurbiprofen is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs) used to treat the inflammation and pain ...

PF 9184
(CAS: 1221971-47-6)

This active molecular is selective mPGES-1 (microsomal prostaglandin E synthase-1 inhibitor. mPGES-1 is an enzyme induced during the inflammatory response and i...

CAS 1033836-12-2 HPGDS-inhibitor-1

HPGDS-inhibitor-1
(CAS: 1033836-12-2)

Chemical Structure

CAS 5104-49-4 Flurbiprofen

Quick Inquiry

Verification code

Featured Items